Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Conditions:   Germ Cell Tumor;   Nonseminomatous Germ Cell Tumor;   Seminoma;   Germinomatous Germ Cell Tumor;   Dysgerminoma;   Pineal Germ Cell Tumor Interventions:   Drug: Durvalumab;   Drug: Tremelimumab Sponsor:   Memorial Sloan Kettering Cancer Center Recruiting - verified May 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials